UNSPSC 51172332: Acetohydroxamic acid

This classification denotes a chelating agent with the molecular formula C2H5NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4RZ82L2GY5, chemically known as hydroxylamine, n-acetyl- but generally known as acetohydroxamic acid, which bears US NIH Compound Identifier 1990. European Medicines Agency schedules Acetohydroxamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05224MIG.

UNSPSC 51172332 Acetohydroxamic acid is a Commodity code nominally covering a specific pharmaceutical intermediate, but the recent state and local opportunities tagged to this code reflect no direct procurement of the chemical itself. The three most recent solicitations under the code span offender drug testing services, pharmaceutical benefit management strategy, and multi-source generic drug supply agreements—none of which center on acetohydroxamic acid as an end product. The mismatch between the code's narrow chemical scope and the breadth of pharmaceutical-services and supply-chain activity in the tagged opportunities suggests either miscoding of the opportunities or a state procurement system that aggregates related chemistry and pharmaceutical handling work under a single taxonomy node. State and local buyers in this space include county community supervision departments, state health and human services agencies, and multi-state cooperative purchasing alliances.

Recent activity appears across Texas and Minnesota, with the most concrete opportunity being Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services, due July 23, 2026, valued at $600,000 over two years with three optional one-year renewals. The Texas Health and Human Services Commission issued a Request for Information in April 2026 on a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling upstream interest in pharmaceutical sourcing strategy but containing no current procurement timeline or award value. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP closing March 26, 2026, for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, effective July 1, 2026, with performance penalties ranging from $200 to $1,500 per violation. The code shows sparse and misaligned recent activity; business development professionals should verify that acetohydroxamic acid itself aligns with their firm's capabilities before pursuing opportunities tagged to this code.